Playing a bit of catch up here, well undervalued even if you consider Didipio redundant. Tier 1 jurisdictions for the other assets, growing production and grade profile.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling